KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Quest Diagnostics (DGX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $2.18.

  • Quest Diagnostics' EPS (Basic) rose 845.77% to $2.18 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.64, marking a year-over-year increase of 1489.36%. This contributed to the annual value of $7.78 for FY2024, which is 250.33% up from last year.
  • According to the latest figures from Q3 2025, Quest Diagnostics' EPS (Basic) is $2.18, which was up 845.77% from $2.51 recorded in Q2 2025.
  • Over the past 5 years, Quest Diagnostics' EPS (Basic) peaked at $5.05 during Q2 2021, and registered a low of $0.93 during Q4 2022.
  • Over the past 5 years, Quest Diagnostics' median EPS (Basic) value was $2.05 (recorded in 2024), while the average stood at $2.42.
  • Per our database at Business Quant, Quest Diagnostics' EPS (Basic) surged by 37567.57% in 2021 and then crashed by 7111.8% in 2022.
  • Quarter analysis of 5 years shows Quest Diagnostics' EPS (Basic) stood at $3.22 in 2021, then crashed by 71.12% to $0.93 in 2022, then soared by 84.95% to $1.72 in 2023, then increased by 15.12% to $1.98 in 2024, then rose by 10.1% to $2.18 in 2025.
  • Its last three reported values are $2.18 in Q3 2025, $2.51 for Q2 2025, and $1.97 during Q1 2025.